Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: Boehringer best in MASH?; biopharma funding on an upswing?; Moderna’s combo jab; clinical trial recover from pandemic; and Astellas’s US commercial head speaks.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 14 June 2024, including: Boehringer Ingelheim GmbH best in MASH?; biopharma funding on an upswing?; Moderna, Inc.’s combo jab; clinical trial recover from pandemic; and Astellas Pharma, Inc.’s US commercial head speaks.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Boehringer Backs Up Best-In-Class MASH Claims With Fibrosis Data" - Scrip, 7 Jun, 2024.)
(Also see "Financial Market At The Start Of An Upswing, For Companies With Focused Strategies" - Scrip, 12 Jun, 2024.)
(Also see "Moderna Pips Pfizer/BioNTech In Combo Jab Race" - Scrip, 10 Jun, 2024.)
(Also see "What Pandemic? Clinical Trials Shake The COVID-19 Dust Off Their Feet" - Scrip, 12 Jun, 2024.)
(Also see "Astellas’s US Commercial Head Petroutsas On New Launches" - Scrip, 11 Jun, 2024.)